SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : VVUS: VIVUS INC. (NASDAQ) -- Ignore unavailable to you. Want to Upgrade?

To: AlienTech who wrote (13452)8/17/1998 1:16:00 AM
From: VLAD  Respond to of 23519
 
alien,

Well if Astra is only beginning sales now in both Sweden and Switzerland, it would appear that Vivus must be selling everything it can produce. Approval in these countries was announced quite some time ago and the only reasonable explanation for this delay would be a lack of product to sell.



To: AlienTech who wrote (13452)8/17/1998 1:19:00 AM
From: AlienTech  Read Replies (2) | Respond to of 23519
 
I though Viagra was approved in the UK? Why does muse still have 53% of the market? Or is it that Viagra is approved but not available?
I would have expected muse sales to drop to under 10%.


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News